

[Mifepristone - misoprostol](#)

Essential medicine status

Section:

[22. Medicines for reproductive health and perinatal care 22.4. Medicines for medical abortion](#)

ATC codes: [G03XB51](#)

Indication

Unspecified time of fetal death, cause not specified ICD11 code: [KD3B.Z](#)

INN

Mifepristone + misoprostol

Medicine type

Chemical agent

List type

Core

Formulations

**Oral > Solid > tablet:** 200 mg + 200 µg ; 200 mg [1] + 200 µg [4] in co-package

EML status history

First added in 2023 ([TRS 1049](#))

Changed in 2025 ([TRS 1064](#))

Sex

Female

Age

Adolescents and adults

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Mifepristone - misoprostol](#)

DrugBank

[Mifepristone](#),

[Misoprostol](#)

Summary of evidence and Expert Committee recommendations

Following recommended changes to Section 22 of the EML, the listings for mifepristone - misoprostol (all indications), and for misoprostol for management of incomplete abortion and miscarriage are moved to the new sub-section for medicines for medical abortion. In addition, the Expert Committee noted the advice of the decision by WHO to remove the boxed text associated with the listing for mifepristone - misoprostol.